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Abstract: Hepatitis B virus (HBV) causes liver diseases that have been a consistent problem for
human health, leading to more than one million deaths every year worldwide. A large proportion
of hepatocellular carcinoma (HCC) cases across the world are closely associated with chronic HBV
infection. Apoptosis is a programmed cell death and is frequently altered in cancer development.
HBV infection interferes with the apoptosis signaling to promote HCC progression and viral
proliferation. The HBV-mediated alteration of apoptosis is achieved via interference with cellular
signaling pathways and regulation of epigenetics. HBV X protein (HBX) plays a major role in the
interference of apoptosis. There are conflicting reports on the HBV interference of apoptosis with
the majority showing inhibition of and the rest reporting induction of apoptosis. In this review, we
described recent studies on the mechanisms of the HBV interference with the apoptosis signaling
during the virus infection and provided perspective.
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1. Introduction
Hepatitis B virus (HBV) is an enveloped DNA virus with a reverse transcription phase, belonging
to the Orthohepadnavirus genus, the Hepadnaviridae family [1,2]. The genome of HBV is only 3.2 kb,
containing four overlapping open reading frames (ORFs). The four ORFs encode seven viral proteins:
pre-S1, pre-S2, S, pre-C, C, viral polymerase, and HBV X protein (HBX). There are four regulatory
elements in the genome: enhancer II/basal core promoter, pre-S1 promoter, pre-S2/S promoter, and
enhancer I/X promoter. The core protein and the viral polymerase are translated from the pre-genomic
RNA (pgRNA), while the regulatory HBX protein and the three envelope proteins are encoded by the
subgenomic RNAs [1,2]. The HBV virions attach to host cells through heparan sulfate proteoglycans or
the hepatocyte-specific pre-S1 receptor, sodium taurocholate cotransporting polypeptide (NTCP) [3].
The virions enter the cells by endocytosis or fusion of the viral envelope at the plasma membrane.
Once entering the cells, the viral nucleocapsid containing the partially double-stranded DNA, known
as the relaxed circular DNA (rcDNA), would be released into the cytoplasm and transported into the
nucleus [2]. The plus strand of the rcDNA is repaired and completed by the viral polymerase in the
nucleus to generate the covalently closed circular DNA (cccDNA), which is transcribed into RNAs
for the viral replication. The HBV DNA can be integrated into the host genome and the integration is
commonly seen in patients with hepatocellular carcinoma (HCC).
HBV infection causes both acute and chronic liver diseases, and accounts for most of the chronic
liver diseases globally, affecting over 240 million people worldwide [4]. More than one million
individuals die from cirrhosis and liver cancer caused by the chronic HBV infection each year [5].
HBV infection is predominantly prevalent in Asian countries, such as China, Japan, Taiwan, and
Korea [6]. In the USA, HBV infection is most common among Asians [7]. Up to now, ten genotypes
(A–J) of HBV have been identified [8]. Genotypes A and D are ubiquitous but prevalent in Europe
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and Africa, while genotypes B and C are confined in Asia and Oceania. Other genotypes (E–J) are
occasionally observed in some Asian countries. The virus can be transmitted through blood, semen, and
body fluid, or from mother to baby at birth [9,10]. For some people, hepatitis B is an acute or short-term
illness; but for others, it can become a long-term, chronic infection [11,12]. This indicates that HBV
infection is just a trigger for liver diseases and HCC development, which are possibly the consequence
of a complex interplay of many factors including host immune response. There is a large proportion
of HBV-inactive carriers, who present little virus replication, normal alanine aminotransferase (ATL)
level and minimal liver inflammation [13]. However, some of them may undergo HBV reactivation
when treated with immunosuppressive drugs or suffer a higher risk of hepatocellular carcinoma after
excessive alcohol consumption [14,15]. Despite an effective vaccine for prevention, there is still no
known cure for existing HBV infection.
The frequent integration (>70%) of HBV DNA into the cell genome contributes to the instability
of the chromosome, interruption of key cellular pathways and mutation of some pro-cancer genes [16].
HCC progression is found to associate with the patient ages and the HBV genotypes. The HBV
genotype A mainly causes acute liver disease in clinical settings. An epidemiological investigation
in China shows that, in young HCC patients (<30 years old), the HBV B2 is predominant, and a
breakpoint in chromosome 8q24 located between c-Myc and plasmacytoma variant translocation 1
(PVT1) is more frequently found than in older patients. HBV integration into this site leads to the
overexpression of c-Myc and PVT1, and consequent HCC progression [17]. Aside from the HBV B2
genotype, the HBV C genotype also accounts for a large number of clinical HCC cases [8].
Chronic HBV infection is often accompanied by HCC. Among all the cancer cases caused by the
infectious agents, 19.2% are attributed to HBV, while 7.8% are caused by hepatitis C virus (HCV) [18].
Some tumor diseases or HCC are frequently accompanied by defective apoptosis. In clinically
histochemical staining of human carcinoma tissues, the Fas-expression is much lower than their
corresponding non-carcinoma tissues, in both frequency and amount. Moreover, the apoptotic cell
percentage is lower in the Fas-defective tissues [19]. During virus infection, the host cells take some
protective measures such as cell death to prevent virus replication or dissemination [20]. To survive in
the host cells, the viruses have evolved various mechanisms to modulate the apoptosis signaling during
infection. They can promote the cell apoptosis and fission to facilitate the virus dissemination, or
antagonize the apoptosis to gain time to proliferate in the infected cells. For example, HCV accelerates
the cell apoptosis by the activation of caspase 3 and the release of cytochrome C, whereas Myxoma
virus produces viral B-cell lymphoma 2 (BCL-2) to prevent the cell apoptosis [21]. In addition, some
oncogenes are also upregulated during virus infection, such as HBV and avian leukemia virus [22,23].
HBX, approximately 17.4 kDa, is a viral protein with multiple functions. This protein can be
translated in host cells from the integrated HBV genome even in the absence of complete virus
replication cycle [24,25]. Thus far, the function of X protein is the most widely studied among
all the HBV proteins. The small regulatory protein is implicated to play a major role in HCC
progression [26–28]. It is able to not only suppress the DNA repair machinery [29,30] but also affect the
DNA methylation of the host cells. These activities might contribute to the HCC progression [31,32].
HBX has also been demonstrated to have interplay with non-coding RNA (ncRNA) and various
signaling pathways to regulate the host cell activities. Since the cell apoptosis is highly correlated with
the HCC progress, understanding how the virus interferes with the apoptotic process may shed light
on the mechanism of HCC formation and facilitate the development of anti-tumor therapeutics. Here,
we summarize recent studies on the mechanisms of HBV interference of the apoptosis.
2. Apoptosis
Apoptosis is a programmed cell death, which is highly organized and acts as a protective strategy
for healthy organisms to maintain the homeostasis [33]. The apoptosis plays a vital role in the innate
and adaptive immune responses. The morphology of apoptotic cells is featured by cell shrinkage,
membrane blebbing and the formation of apoptotic bodies [34–36]. Apoptotic cells do not release their
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cellular contents to the surroundings before being phagocytosed in vivo. The predominant pathways
of the apoptosis are mainly composed of the extrinsic pathway (death receptor pathway) and the
intrinsic pathway (mitochondrial pathway) [37].
The extrinsic pathway is mostly triggered by the external stimuli such as Fas, tumor necrosis
factor-α (TNF-α), TRAIL (TNF-related apoptosis-inducing ligand), APO3L and APO2L [37]. Binding
of the extracellular ligands to their receptors on the cell surface leads to the recruitment of adaptor
proteins to transmit the intracellular signals via the caspase cascades. The recruited caspase 8422
and Fas-associated protein with death domain (FADD) forms an oligomeric death-inducing signaling
complex (DISC), leading to the cleavage and activation of caspase 8. The activated caspase 8 then
cleaves and activates the effector caspase 3/7, which are able to cleave a broad spectrum of cellular
targets, such as receptor-interacting protein (RIP), X-linked inhibitor of apoptosis protein (X-IAP),
signal transducer and activator of transcription-1 (STAT1), topoisomerase I, vimentin, retinoblastoma
(Rb), and lamin B, consequently resulting in the cell death [38–40]. For the TNF receptor (TNFR), upon
activation, TNFR recruits adaptor proteins TNFR type 1-associated DEATH domain protein (TRADD),
Fas-associated protein with death domain (FADD), receptor-interacting serine/threonine-protein
kinase 1 (RIPK1), cellular inhibitors of apoptosis (cIAP), TNF receptor associated factors 2 (TRAF2),
and TRAF5. These proteins form the complex I (Figure 1), which leads to initiation of the canonical
nuclear factor kappa-light-chain-enhancer of activated B cells (NF-κB) pathway [41]. In the complex
I, IAPs can exert an anti-apoptotic role in the cells, for instance, cIAP1/2 interact with the second
mitochondrial activator of caspases (SMAC) and sequester it from the XIAP, and the released XIAP
inhibits caspases and apoptosis [42,43]. However, the anti-apoptotic role of cIAP1 can be counteracted
by the SMAC mimetics [44]. Under certain circumstances, such as loss of cIAP, a secondary death
promoting complex, termed as the complex II, can be formed. The complex II is composed of TRADD,
FADD, RIPK1, caspase 8, and is capable of inducing apoptosis or necroptosis [45–47]. Notably, the
complex II-initiated apoptosis can be prevented by cellular FLICE-inhibitory protein (cFLIP) through
the inhibition of caspase 8 activity [48]. The expression of cFLIP is mediated by the NF-κB signaling.
The intrinsic pathway is initiated by the internal stimuli, such as DNA damage, endoplasmic
reticulum (ER) stress, hypoxia and metabolic stress [37]. In healthy cells, the BCL-2 sequesters
its proapoptotic counterparts, BAX (BCL-2-associated X protein), BAK (BCL-2 homologous
antagonist/killer), and BCL-2 homology domain 3 (BH3)-only proteins into inactive complexes.
Under cell stress, BH3-only proteins are activated, followed by the release of BAK/BAX and the
engagement of the homo-oligomerization of the two proteins. The self-association of BAK/BAX is
inclined to form a lipidic pore in the outer membrane (OM) of mitochondria by inserting α-helices
5 and 6 of the dimer into the OM, resulting in mitochondrial outer membrane permeabilization
(MOMP) [49,50]. The MOMP allows inner mitochondrial proteins, such as apoptosis inducing factor
(AIF), SMAC and cytochrome C, to be released into the cytosol. While SMAC exerts its pro-apoptotic
role through binding with cIAPs, cytochrome C interacts with apoptotic protease activating factor
1 (APAF1) to facilitate the formation of the apoptosome. Once formed, the apoptosome will then
recruit and activate the pro-caspase 9. The cleaved pro-caspase 9 becomes active and then activates the
caspase 3/7, culminating in the cell apoptosis [51,52].
In addition to the caspase-dependent intrinsic pathway, the AIF protein can induce apoptosis
by triggering chromatin condensation and DNA fragmentation, independent of caspase activation.
After being released from the mitochondria, AIF ends up in the nucleus where it signals
the cell to chromosome condensation and DNA fragmentation by Ca2+ and Mg2+-dependent
endonucleases [53,54].
The extrinsic pathway and the intrinsic pathway have some crosstalk via protein BH3
interacting-domain death agonist (BID). The activated caspase 8 is demonstrated to cleave BID, which
belongs to the “BH3-domain-only” subset of the BCL-2 family. The truncated BID (tBID) triggers BAK
or BAX homo-oligomerization and consequently MOMP [55]. In the process of apoptosis, the level of
reactive oxygen species (ROS) plays an important role in deciding the cell fate. It interferes with both
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the extrinsic and the intrinsic pathways. Low-level ROS promotes the cell survival signaling, while
toxic level ROS induces cell apoptosis [56]. The cancer cells usually have higher level ROS and are more
capable to scavenge excessive ROS than the normal cells [57]. The higher level of ROS enhances cell
proliferation through inducing abnormal cell growth caused by genetic mutation, enhanced autophagy,
or activation of various signaling pathways, such as the phosphatidylinositol-4,5-bisphosphate
3-kinase-protein kinase B (PI3K-Akt) pathway, NF-κB, and protein kinase D (PKD) pathway. The toxic
level of ROS leads to the apoptotic death of cancer cells.
Apart from the two extensively studied pathways, there are the physiological pathway, the
perforin/granzyme pathway, and the pathological apoptosis pathway. In order to maintain the
homeostasis of the human body, numerous cells need to be sacrificed every day to balance the
metabolism. For instance, during the development of immune system, most lymphocytes lacking B cell
receptor (BCR) or T cell receptor (TCR) will be eliminated by selection process [58]. Some diseases also
cause excessive apoptosis in human tissue. A classic example is that the human immunodeficiency
virus (HIV) Tat protein increases the Fas expression of CD4+ T cells, increasing the possibility of T cell
elimination [59]. The perforin/granzyme B pathway is one of the mechanisms that the cytotoxic
T lymphocytes (CTL) and natural killer (NK) cells utilize to kill their target cells. The perforin
forms poly-perforin pores on the target cell membrane, inducing the osmotic instability and allowing
granzyme B to pass through the cell membrane to cause cell lysis. This mechanism can lead to cell
death in the absence or presence of the activated caspases [60].
3. Hepatitis B Virus and Apoptosis
Plenty of studies have been performed to determine the relationship of HBV infection and
apoptosis, but the results are still contradictory. The majority of the papers showed that HBV or
HBX could inhibit the cellular apoptosis, thereby facilitating the virus proliferation and promoting
the HCC progression [61–63]. Various studies have been done to define the balance among the HBV
proliferation, apoptosis and HCC. For long-term persistence in the host cells, HBV may inhibit cell
death by either activating oncogenes or disrupting signaling pathways, thereby promoting the HCC
progression. HBV can also inhibit apoptosis and promote HCC development through the upregulation
of some pro-growth proteins, such as cationic amino acid transporter 1 (CAT-1) [64]. In some clinical
cases, the CTL response is also relatively weak in chronic HBV patients, culminating in apoptosis of
a smaller proportion of infected hepatocytes [65,66]. In chronical HBV-infected mice, cIAPs restrict
the TNF-mediated HBV elimination as well as HBV-infected hepatocytes death, while the inhibition
of cIAPs by SMAC mimetics or silence of cIAPs boosts HBV clearance in the presence of TNF and
HBV-specific CD4+ T cells [67,68]. On the other hand, HBV induction of apoptosis is also reported
in some papers [69–74]. The reason for the discrepant results of HBV effect on apoptosis is not
known, but possibly due to the different experimental conditions or the HBV genotypes used in the
different laboratories.
3.1. Inhibition of Apoptosis by Hepatitis B Virus
Among the HBV proteins, HBX is the most frequently reported one to be associated with the
inhibition of apoptosis and the activation of HCC progression. It may block apoptosis through
the sequestration of cytoplasmic p53, activation of PI3K-Akt pathway, inhibition of death receptor
mediated apoptotic pathway, activation of NF-κB signaling pathway, inhibition of mitochondrial
apoptotic pathway, as well as interplay with ncRNA [75–80]. The mechanisms of HBX inhibition of
apoptosis are summarized below (Figure 1).
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Figure 1. Inhibition of apoptosis by hepatitis B Virus (HBV) infection. Hepatitis B Virus X protein 
(HBX) and HBV core inhibit p53-mediated apoptosis. HBX activates the phosphatidylinositol-4,5-
bisphosphate 3-kinase-protein kinase B (PI3K-Akt) pathway to inhibit apoptosis via the upregulation 
of PI3K and the induction of Akt phosphorylation. HBX inhibits the intrinsic apoptotic pathway by 
recruitment of Drp-1 and Parkin to the mitochondria for mitochondrial fission and mitophagy. The 
activation of Akt also prevents translocation of BAD to the mitochondria, thereby preventing 
apoptosis. HBX can activate the nuclear factor kappa-light-chain-enhancer of activated B cells (NF-
κB) signaling via the degradation of IκB. In the MAPK-JNK pathway, HBV can attenuate the function 
of the kinase that activates JNK. HBV can downregulate apoptosis by either elevation of anti-
apoptotic ncRNAs such as MiR-181a, or decrease of pro-apoptotic ncRNAs, such as MiR-29c. Green 
arrows next to the white boxes (HBV or HBV proteins) denote the activation of apoptosis. Red bars to 
the white boxes stand for the inhibition of apoptosis. Drp-1: Dynamin-1-like protein. BAD: BCL-2-
associated death promoter. MAPK: MAP kinase. JNK: c-Jun N-terminal kinases. ncRNA: Non-coding 
RNA. MiR-181a/29c: MicroRNA 181a/29c. 
3.1.1. Sequestration of p53 Signaling 
P53, a tumor suppressor, is not only a transcription factor that regulates the expression of a variety 
of genes but also induces apoptosis [81,82]. A Japanese research group shows that by expressing HBX 
in HepG2 and HLF cells with Cre/Lox system, apoptosis is induced independently of p53 [83]. In 
contrast, HBX is demonstrated to be capable of abolishing p53-induced apoptosis by binding it (Figure 
1) [75,84]. Mutations of nucleotides, A1762T and G1764A, of HBX are frequently reported in HBV 
isolated from chronically infected patients. The mutant HBX promotes the replication of HBV (subtype 
adw2), resulting in a higher viral load in hepatoma cells [85,86]. In HepG2.2.15 cells, the mutant HBX 
binds to p53 and blocks its downstream gene transcription, while the wild type HBX (subtype ayw) only 
binds to p53 without affecting the p53-mediated transcription [87]. In addition, the restriction of p53 
signaling by HBX may vary in different cell types. In primary human hepatocytes, the wild type HBX 
(genotypes ayw and adr) is able to quench p53 in the cytoplasm, and the C terminal portion of HBX is 
responsible for the sequestration [88,89]. In contrast, in HepG2 and Hep3B tumor cells, HBX is pro-
apoptotic and enhances the nuclear translocation of p53 through the activation of ATM kinase, which 
phosphorylates p53. However, in a later study, the inhibition of p53 by HBX could only be achieved 
when p53 is expressed at a relatively high level in the cells (HepG2, Hep3B and NIH/3T3 cells) [90]. The 
hepatoma upregulated protein (HURP), a cellular oncogene that mediates the degradation of p53, is 
upregulated by HBX in HCC, and consequently, inhibits the cisplatin-induced apoptosis [62]. Although 
the HBX and p53 interaction is reported, transduction of HBX in transgenic mice indicates that this 
interaction is not sufficient for tumor formation [91]. Therefore, the HBV-mediated inhibition of 
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3.1.1. Sequestration of p53 Signaling
P53, a tumor suppressor, is not nly a transcription factor that regulates the expression of a variety
of gen s but also induces apopt sis [81,82]. A Japanese research group shows that by expr ssing HBX in
HepG2 and HLF cells with Cre/Lox system, apoptosis is induced i epende tly of p53 [83]. In contrast,
HBX is demonstrated to be capable of abolishing p53-induced apoptosis by binding it (Figure 1) [75,84].
Mutations of nucleotides, A1762T and G1764A, of HBX are frequently report d in HBV is lated from
chronically infe ted patients. The mutant HBX promotes the replication of HBV (subtype adw2),
resulting in a h gher viral load in hepatoma c lls [85,86]. In HepG2.2.15 cells, the mutant HBX binds to
p53 and blocks its downstream ge e transcription, while he wild type HBX (subtype ayw) only binds to
p53 without affecting the p53-mediated transcription [87]. In addition, the res riction of p53 signaling
by HBX may vary in different cell typ s. In primary human hepatocytes, t wild type HBX (genotypes
ayw a d adr) is able to quench p53 in th cytoplasm, and the C termi al portion of HBX is resp nsible
for the sequestration [88,89]. In c trast, in HepG2 and Hep3B tumor cells, HBX is p o-apoptotic and
enhances he uclear tran location of p53 thr ugh the activation of ATM kinase, which phosphorylates
p53. However, in a later study, the inhibition of p53 by HBX c uld only be achieved when p53 is
expressed at a relatively high l vel in the cel s (HepG2, Hep3B and NI /3T3 cells) [90]. he hepatoma
upr gulated prot in (HURP), a cellular oncogene that mediates e degradation of p53, is upregulated
by HBX in HCC, and co sequently, inhibits the cisplatin-induced apoptosis [62]. Although the HBX
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and p53 interaction is reported, transduction of HBX in transgenic mice indicates that this interaction
is not sufficient for tumor formation [91]. Therefore, the HBV-mediated inhibition of apoptosis through
the interference of p53 may be dependent on cell types, experimental models, HBX structure and
p53 level.
3.1.2. Activation of PI3K Pathway
In many cancers, the PI3K-Akt pathway is overactive, thus reducing apoptosis and allowing
cell proliferation (Figure 1) [92]. Akt is normally considered as an anti-apoptotic protein through
antagonizing pro-apoptotic proteins or facilitating the induction of other anti-apoptotic proteins [93–96].
In HBX-overexpressed Hep3B cells and 293T cells, Akt is activated to phosphorylate IκB kinase (IKKα)
and promote its nuclear translocation, which is found to promote cell migration and invasion [97].
In Chang liver cells, HBX activates the PI3K-Akt, leading to the phosphorylation and blockade of
BCL-2-associated death promoter (BAD), a pro-apoptotic protein inducing mitochondrial permeability
transition pore (MPTP). Consequently, the cytochrome C release and apoptosis are prevented [98]. In a
human placental trophoblastic cell line, HBX inhibits apoptosis via the elevation of PI3K expression to
strengthen the activity of the PI3K-Akt pathway [99]. In addition, the transforming growth factor beta
(TGF-β)-induced apoptosis in Hep3B cells can be rescued by the HBX-activated PI3K-Akt pathway [76].
A previous study shows that the anti-apoptotic effect of HBX is dependent on its isoforms [100].
The HBX isoform that contains the Akt phosphorylation site at Ser31 functions as an anti-apoptotic
protein. This isoform can be phosphorylated by Akt and in turn activate the PI3K-Akt pathway.
In contrast, the isoform that does not contain the Akt phosphorylation site plays an opposite function
in apoptosis [100].
3.1.3. Inhibition of the Death Receptor-Mediated Apoptotic Pathway
In the extrinsic apoptotic pathway, HBX potently inhibits the caspase 3 activity [79,101]. HBX
has been shown to inhibit the Fas-induced apoptosis, and this process is independent of p53 [79].
In this study, HBX transfection rate in primary hepatocytes is significantly enhanced from 5% to
80% by co-expressing HBX and enhanced green fluorescence protein (EGFP). Simultaneously, HBX
inhibited the activation of caspase 8 and 3 and the release of cytochrome C. The HBX expression
is associated with the upregulation of SAPK/JNK signaling, and furthermore, the 26RXRXXS motif
of HBX is essential for the SAPK upregulation and the inhibition of Fas-mediated cell killing. HBX
induces the activation of NF-κB signaling via the degradation of inhibitor of kappa B (IκB), which also
contributes to the inhibition of Fas-induced apoptosis (Figure 1) [63,102].
3.1.4. The Activation of NF-κB Pathway
NF-κB is generally regarded as a positive regulator of cell growth [103–105]. The NF-κB signaling
consists of the canonical and the non-canonical NF-κB signaling pathways (Figure 1). The canonical
NF-κB signaling is initiated through receptors such as toll-like receptors (TLRs), tumor necrosis factor
receptor (TNFR), T-cell receptor (TCR) or B cell receptor (BCR). The receptor-mediated activation
of transforming growth factor beta-activated kinase 1 (TAK1) phosphorylates IKK complex, which
consequently degrades IκB, leading to the release of NF-κB heterodimer (p65/p50) into the nucleus.
The non-canonical pathway is triggered by a signaling from a subset of TNFR members, such as B cell
activating factor receptor (BAFFR), CD40, lymphotoxin β-receptor (LTβT) and receptor activator for
nuclear factor κB (RANK). Through the activation of NF-kappa-B-inducing kinase (NIK) and IKKα,
p100 is processed into the active p52, which forms a heterodimer with RelB. The subsequent nuclear
translocation of the RelB/p52 results in a persistent stimulation of the pathway [106]. Moreover, the
accumulation of NIK is reported to activate the canonical NF-κB pathway through the enhancement of
IKK complex activity [107]. In the process, the anti-apoptotic protein IAPs can both positively and
negatively regulate the canonical or the non-canonical NF-κB signaling. For instance, upon engagement
of TNFR (see Section 2), the cIAP in complex I promotes the ubiquitination of RIPK1, which leads to the
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activation of TAK1 [108]. In addition, the ubiquitinated RIPK1 can prevent apoptosis by suppressing
the formation of complex II and the activation of caspase 8. In contrast, IAPs also exert an inhibitory
role in the NF-κB pathways. For example, the basal level of NIK activation is very low due to the
control of upstream TRAF3-TRAF2-cIAP complex, and cIAP1/2 degrades NIK by ubiquitinating the
protein, while the loss of any component of the complex leads to an accumulation of NIK and the
activation of both NF-κB signaling pathways [107,109–111].
The NF-κB signaling is constitutively activated in many cancers, and the NF-κB activation
contributes to tumorigenesis [112,113]. There are several mechanisms that NF-κB antagonizes cell
death. First, the NF-κB activation leads to an elevation of anti-apoptotic genes. Secondly, NF-κB
induces the production of immune response cytokines, such as TNF-α, IL-1 (Interleukin-1), IL-6, and
IL-8. Moreover, NF-κB induces the expression of some pro-oncogenic genes, such as cyclin D1, c-Myc,
and cIAPs [114]. In addition, the NF-κB signaling contributes to tumor progression by facilitating
epithelial to mesenchymal transition and metastasis, as well as aiding the vascularization of tumors
via the upregulation of vascular endothelial growth factor (VEGF) [115–117]. The activation of NF-κB
signaling increases the stability of HBX protein [118]. Several studies have demonstrated that HBV
infection leads to the activation of NF-κB, followed by the inhibition of apoptosis and increase of cell
progression (Figure 1) [119–124]. HBX induces the activation of NF-κB by degrading IκB [119,120].
IκB is responsible for sequestering NF-κB in the cytoplasm. Once IκB is phosphorylated and degraded,
the NF-κB heterodimer translocates into the nucleus and initiates the transcription of downstream
genes. To examine the correlation between NF-κB activation and apoptosis, IκB-SR, an isoform that
cannot be phosphorylated, is introduced into NIH/3T3 cells. The cotransfection of IκB-SR and HBX
results in increased apoptosis [121]. In the presence of IκB-SR, HBX overexpression induces MPTP.
Notably, in the context of HBV replication, HBX activates NF-κB and inhibits the cytochrome C release
from the mitochondria. However, when the NF-κB activity is inhibited, the HBX in the context of HBV
replication could induce apoptosis through MPTP. This study indicates that, depending on the status of
NF-κB activity, HBX can be either pro- or anti-apoptotic [122]. In the HBV-positive cell line, HepG2.2.15,
the cIAP1 and cIAP2 are expressed much higher than in HepG2, indicating that HBV replication might
boost the anti-apoptotic proteins [78]. In addition, the activation of NF-κB is found to initiate enhanced
transcription of both anti-apoptotic genes such as gp96, survivin, p21 and the pro-apoptotic genes
such as death receptor 5 (DR5) [123]. The expression of the anti-apoptotic genes may be responsible for
the multidrug resistance of HBX-transfected HepG2 cells [124]. On the other hand, the upregulation of
death domain receptor accounts for the increased sensitivity of cells to apoptotic stimuli. In different
cell lines, the regulation effect of HBX also varies [125]. To illustrate this point, two HBX-expressing
stable cell lines were established, namely, Huh-7-X and CHANG-X. The mRNA levels of p21, p27,
and TGF-β are drastically downregulated in Huh-7-X stable cells but have a minimum change in
CHANG-X stable cells [125]. Collectively, the NF-κB signaling is important not only in the innate
immune system but also in the release of cell stress and the promotion of hepatocytes growth, as well
as in the regulation of apoptosis upon HBV infection.
3.1.5. Inhibition of the Mitochondria-Mediated Apoptotic Pathway
Sequence analysis from tumor tissues and para-tumor tissues of 47 patients shows a combination
of mutations (10Ala/Arg and 144Ser/Arg) exists in HBX with high frequency [61]. HBX harboring
these two mutations reduces BAX expression and inhibits apoptosis in HepG2 cells. HBX is also
able to inhibit serum-starvation induced mitochondrial apoptosis via the activation of autophagy,
which is featured by increased microtubule-associated proteins 1A/1B light chain 3B (LC3II) and
Beclin-1 [126,127]. As a core component of PI3K-III complex, Beclin-1 plays an important role in
autophagy and cell death [128], while the interaction between BCL-2 and Beclin-1 does not counteract
the anti-apoptotic role of BCL-2 [129]. HBX can sequester AIF, a caspase-independent protein in
the intrinsic pathway, in the cytoplasm, resulting in the prevention of DNA fragmentation and
apoptosis [130]. In Huh-7 cells, HBV and HBX can disrupt mitochondrial dynamics by inducing the
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translocation of dynamin-related protein Drp-1 to the mitochondria and the subsequent mitochondrial
fission [77]. Parkin, an E3 ligase, is also translocated to the mitochondria and associated with
the mitophagosome triggered by HBV/HBX. Parkin expression is upregulated in the presence of
HBV/HBX. The enhanced Parkin level promotes the mitophagy, which attenuates apoptosis. Silencing
of Parkin induces the mitochondrial apoptotic signaling. Thus, HBV promotes aberrant mitochondrial
dynamics to protect cells from apoptosis in HepAD38 cells [77]. In chronic HBV-infected patients,
the mitochondrial polarization in CD8+ T cells is impaired, and a higher level of ROS is detected in
chronic patients in comparison with healthy individuals [131]. Further, the restoration of mitochondrial
function via mitochondria-targeted antioxidants reactivates the exhausted T cells and helps with HBV
clearance in the chronic HBV patients [131].
3.1.6. Interference of Apoptosis through ncRNA
NcRNA accounts for 90% of genomic RNA, and it can be divided into the long non-coding
RNA (lncRNA) and the microRNA (miRNA or MiR hereafter) [132]. Recently, increasing studies
show that ncRNA has essential biological functions such as modulating cell proliferation, cell cycle,
apoptosis, invasion and metastasis in cancers [133]. The interaction of HBV and ncRNA has also
been widely studied. HBV and HBX inhibit the cell apoptosis by the interference of ncRNA. This is
supported by the observation that HBV or HBX-transfected HepG2 cells have significantly upregulated
MiR-181a and decreased PTEN, a tumor suppressor protein. PTEN inhibits PI3K-Akt and protects
p53 by attenuating the mouse double minute 2 homolog (Mdm2) translocation into the nucleus
(Figure 1) [134]. Upregulation of miR-181a suppresses PTEN expression, and inhibition of miR-181a
abolishes the inhibitory effect of HBX on PTEN protein [135]. A novel lncRNA DBH-AS1 has been
shown to activate ERK/p38/JNK MAPK (extracellular signal-regulated kinases/p38/ c-Jun N-terminal
kinases mitogen-activated protein kinase) signaling and promote cell proliferation. HBX promotes
the generation of DBH-AS1, thereby inhibiting serum starvation-induced apoptosis in HCC [136].
MiR-221, promoting cell proliferation by suppression of estrogen receptor-α, is also obviously increased
in HBX-transfected HCC cells [137]. Aside from the function of HBV proteins, HBV transcripts in
transgenic mice absorb the MiR-15a/16 and increase expression of the anti-apoptotic proteins BCL-2
and Smad7 [138,139].
In HBV-transfected HCC cell lines and clinical tumor tissues, pro-apoptotic microRNA MiR-29c is
significantly downregulated [80]. The MiR-29c inhibits cell proliferation through suppressing A20, an
E3 ligase negatively regulating NF-κB signaling and TNF-induced apoptosis via downregulating the
E3 ligase activity of TRAF2 and TRAF6 (Figure 1) [140]. In HBV-related HCC patients, the MiR-122 and
MiR-22 are significantly lower than those in benign liver diseases and non-HBV-related HCC patients,
underlying that the miRNAs play vital roles in the HBV-related HCC formation [141]. These data
suggested that ncRNA could possibly play an important role in the regulation of cell progression,
either positively or negatively, while HBV may interfere with cell apoptosis through the modulation of
those ncRNAs. The research progress on the interplay between ncRNA and apoptosis during HBV
infection is recently reviewed in detail by Zhang et al. [142].
3.1.7. Other Inhibitory Pathways
In addition to the signaling pathways described above, HBV also inhibits apoptosis by the
upregulation of pro-oncogenesis genes or the activation of cell progression pathway. For instance, cell
division control protein 42 homolog (CDC42), a member of the Rho GTPase family, is known to facilitate
tumorigenesis and cancer progression. It is upregulated in HBX-overexpressed Huh-7 cells, resulting
in higher cell proliferation and reduced apoptosis [143]. Manganese superoxide dismutase (MnSOD) is
responsible for scavenging superoxide anion and preventing cells from DNA damage. HBV infection
increases the expression of MnSOD, which is mediated by HBX protein [144]. Notch signaling and
Smad pathway promote cell proliferation, while, in HCC and HTR-8/SVneo cells, HBX expression
activates these pathways to suppress apoptosis [145,146].
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3.2. Pro-Apoptotic Effect of HBV and HBX
Although the suppression of apoptosis contributes to the progression of carcinogenesis, apoptosis
can still be observed in untreated malignant tumors [147]. The apoptosis could be induced by CTL
in tumor tissue or could be activated by TNF-α treatment [72,148]. HBV can also activate apoptosis
or sensitize host cells to apoptosis induction in in vitro studies, through the direct activation of
apoptotic proteins, regulation of Ca2+ concentration or the upregulation of cell death receptors [149,150].
Following are signaling pathways that HBV interrupts to induce cell apoptosis (Figure 2).
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Figure 2. Pro-apoptotic role of HBV. HBV infection causes the activation of NF-κB in hepatoma
cells, and subsequent excessive expression of the death-associated receptors, which increase the cell
sensitivity to stimuli. In addition, HBV directly induces the cleavage of caspase 3 to activate apoptosis.
HBV induces the mitochondrial apoptotic signaling pathway by increasing the BAX expression and the
ROS level or downregulating Mcl-1. The BCL-2 homology domain 3 (BH3)-like domain in HBX also
plays a role in the induction of apoptosis. Green arrows mean the activation step of apoptosis; Red
bars stand for the inhibition step of apoptosis.
3.2.1. Death Receptor-Mediated Signaling Pathways
HBV has been reported to induce apoptosis in liver biopsies of HBV patients [151]. The virus
infection in transgenic mice and hepatocytes increases the cell sensibility to TRAIL-induced apoptosis
by increasing the expression of BAX (Figure 2) [73]. HBX expression in hepatocytes has the same
outcome as HBV infection. In clinical HBV liver samples, the TRAIL expression in chronic hepatitis
B samples is the highest in comparison to acute hepatitis B samples, liver cirrhosis, and normal liver
samples. This result suggests that TRAIL expression may have some correlation with the extent of
liver injury [152]. Further studies show that the death receptor TRAIL-R5 expression is enhanced by
HBX in Huh-7 cells through the activation of the NF-κB pathway, which contributes to the increased
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apoptosis induced by TRAIL [74]. Although A20 is upregulated in HBV-infected HCC cells, liver
tissue, and serum of chronic HBV-infected patients [80,153], HBX overexpression in hepatocytes leads
to A20 reduction [154]. HBX sensitizes the hepatocytes to the TRAIL-induced apoptosis by repressing
the A20 expression and its ubiquitin ligase activity (Figure 2) [154].
In addition to TRAIL, HBX is also able to sensitize cells to the TNF-α-induced apoptosis through
the activation of MAP kinase kinase kinase/c-Jun N-terminal kinases (MEKK/JNK) signaling pathway
and the nuclear accumulation of N-Myc [72], or by decreasing the expression of Bcl-xL [155].
Another death receptor, Fas, and its ligand FasL are upregulated in rat renal tubular epithelial cells
(NRK-52E) transfected with HBX, and this increase is due to the activation of the MLK3-MKK7-JNK
pathway [156]. The Fas sensitivity is reconstituted in HBX transgenic mice through the decrease of
BCL-2, despite no direct interaction between HBX and BCL-2 family members [70]. Another group
demonstrates that HBX activates the p38 MAP kinase and JNK pathways, inducing the transcription
of Fas/FasL and TNFR1/TNF-α. The increased expression of death receptors induces the cleavage of
pro-caspase 8, with subsequent tBID activation and cytochrome C release [150]. In addition, a recently
identified novel ORF of HBV, HBwX that fuses HBX and its upstream 56 amino acid residues, has been
shown to sensitize HCC cells to the adriamycin (ADM) and LPS-induced apoptosis [157].
3.2.2. The Mitochondria-Mediated Cell Death
The interaction between HBV and the mitochondria-mediated apoptosis is extensively studied.
HBX overexpression contributes to the aggregation of the mitochondria, leading to cell death [158].
In the same study, HBX was found to colocalize with p53, but this association has no correlation
with mitochondrial aggregation, suggesting two independent mechanisms in apoptosis induction.
HBX binds to BAX in HepG2 cells, leading to enhanced translocation to the mitochondria, followed by
loss of mitochondrial membrane potential [71]. Aside from the pathways mentioned above, HBV also
sensitizes HL7702 cells to the oxidative stress-induced apoptosis through increasing the opening of
MPTP [159]. The Mcl-1, a member of the anti-apoptotic BCL-2 family, is drastically declined during
this process (Figure 2) [160].
BH3-like protein is an important initiator of the mitochondrial apoptotic pathway. Both HBX and
a spliced viral protein, HBSP, have BH3 domain. Both proteins induce caspase 3 dependent apoptosis
in HepG2 cells, while an amino acid mutation in the BH3 domain results in loss of the capability to
induce apoptosis [161]. Possibly due to mutations in the BH3 domain of genotypes A and C of HBV,
the two genotypes have weaker pro-apoptotic activity than genotype B in HepG2 cells [162]. Further
study shows that HBX causes apoptosis in Caenorhabditis elegans by targeting BCL-2 homolog protein
CED9, through the interaction between the BH3 domain and CED9 [163]. However, a recent structural
and biochemistry analysis presents an opposite result, that is, the interaction between BCL-2 and
HBX BH3-like domain is much weaker than the canonical BH3 and BCL-2 [164], indicating that the
mechanism of HBX BH3 motif interfering with BCL-2 might be different. In addition, HBV has been
shown to induce oxidative stress, accompanied by increased ROS level [165].
3.3. The Roles of the Other HBV Proteins
Aside from HBX protein, the other HBV proteins also have roles in cell apoptosis, either positive
or negative. For example, HBsAg prevents the translocation through interaction with jumping
translocation breakpoint protein (JTB), thereby inhibiting cell apoptosis mediated by JTB [166].
The large HBsAg glycoprotein inhibits apoptosis by activating the Src/PI3K/Akt pathway through
the activation of Src kinase (Figure 1) [167]. Simultaneously, a prevalent mutant large HBsAg protein
with the deletion of amino acids 2 to 55 of the pre-S2 region, enhances the expression of pro-survival
BCL-2 proteins; and BCL-2 contributes to 5-fluorouracil resistance in Huh-7 cells [168]. In addition, the
HBV core protein inhibits apoptosis in HepG2 cells via the downregulation of Fas, p53 and FasL [169].
Another group shows that the core protein impairs the phosphorylation of mitogen-activated protein
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kinase kinase 7 (MKK7) by binding to its scaffold protein, RACK1, which consequently down-regulates
JNK pathway and sensitizes HepG2 cells to TNF-α-induced apoptosis (Figure 1) [170].
4. Conclusions and Perspective
As an HCC-associated virus, HBV has drawn a lot of attention. To investigate the virus–cell
interaction, a series of cell models are used in the experiments [171]. Primary human hepatocytes are the
most physiologically relevant in vitro model for HBV infection with the natural viral receptor. However,
the constraints of this cell model cannot be ignored, such as the limited span of life, limited sources and
disparity from different donors. Huh-7 and HepG2 cell lines are commonly used in the studies, though
tumor cells can only partially represent the physiological hepatic functions. To overcome the in vitro
virus culture problem, hepatocyte cell lines stably transduced with HBV (HepAD38 and HepG2.2.15)
are established as a source of HBV infectious particles [3,172–174]. However, the stable cell lines are
not susceptible to HBV infection due to the lack of efficient receptors [175,176]. To obtain an efficient
HBV replication, HepG2 cells stably expressing the HBV receptor (NTCP) have been established and
might be useful for the basic research of HBV biology [3,174].
Although the HCC development is usually featured by the inhibition of apoptosis, the outcome of
cell apoptosis is a result of a complex biological process, as there are different regulations of multiple
cell signaling pathways by the various HBV proteins. Even the same apoptotic signaling pathway can
be affected towards opposite consequences in the cells, such as the mitochondrial apoptotic pathway.
This pathway can be activated by the BAX insertion into the mitochondrial membrane, which is driven
by HBV (Figure 2). In contrast, this pathway can be inhibited by the recruitment of Parkin and Drp-1
during HBV infection (Figure 1). Activation of NF-κB signaling is a double-edged sword: promoting
the expression of pro-survival genes to facilitate the cell proliferation and upregulating the expression
of the death-associated receptor to sensitize cells to apoptotic stimuli. In the cell models with HBX
overexpression, one of the potential considerations is that the protein overexpression level should
mimic the “physiological level” in the HBV-infected patients, which can be achieved by optimization of
transfection or a vector with a mild promoter [177]. In HepG2 cells, the HBX-deficient HBV replication
can be rescued even when HBX is expressed at a very low level (beyond the detection limit of Western
Blotting) [178]. The HBX functions identified in transiently transfected cells can be further assessed
in HBV cell culture models. Therefore, the HBV effect on cell apoptosis varies depending on cellular
context, different signaling pathways, HBV genotypes, protein mutations and possibly different
clinical stages.
Technically, the cell culture models exhibit certain extent of defect due to its failure to mimic the
host microenvironment. The mechanism of interaction between the virus and cell apoptosis should be
further investigated under a more comprehensive situation. It is worthy to note that the frequently
used cell line in the HBV biology study, Chang cells, are reported to have HeLa cell contamination at
least in several clones [179]. Additional caution is needed when using this cell model in further studies.
Although apoptosis induction is widely considered as a positive strategy against cancer, the
apoptotic cells are able to promote proliferation of the surrounding tumor cells by affecting the
microenvironment [180–182]. In addition, there is no exact study of HBV effect on cell apoptosis in
different clinical stages. Since HBV is frequently detected in clinical HCC cancers, it is more relevant
that HBV/HBX accelerates cell transformation and facilitates apoptosis inhibition as a long-term
effect. In most studies, HBV/HBX is shown to promote the anti-apoptotic proteins or inhibit the
function of pro-apoptotic proteins. However, in some experiments, the higher level of ROS or the
upregulated death associated receptors in the hepatocytes might be factors for apoptosis induction.
In addition, co-effect of HBV/HBX levels in infected patients and the stimulation from the surrounding
environment needs to be considered. We postulate there might be certain signaling-competing
mechanism during the disease progression under the comprehensive effect of these myriad factors.
The HBV levels in patients with acute or chronic HBV infection may be monitored and analyzed for
correlation with outcomes in different clinical stages, if possible. Due to the limited host range of the
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virus, the establishment of an efficient animal model is experimentally important. According to the
sequence analysis, duck hepatitis B virus and woodchuck hepatitis virus may be surrogate viruses in
the HBV biological study. In addition, transgenic mice are frequently used in the pathogenesis and
immune response studies of HBV infection. A more advanced experimental model is much needed to
better elucidate the interaction mechanism between HBV and apoptosis.
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Abbreviations
TNF-α Tumor necrosis factor alpha
TRAIL TNF-related apoptosis-inducing ligand
APO2L APO2 ligand
APO3L APO3 ligand
BCL-2 B-cell lymphoma 2
BAK BCL-2 homologous antagonist/killer
FADD Fas-associated protein with death domain
DISC death-inducing signaling complex
RIP receptor-interacting protein
X-IAP X-linked inhibitor of apoptosis protein
TRADD TNFR type 1-associated DEATH domain protein
RIPK1 receptor-interacting serine/threonine-protein kinase 1
cIAP cellular inhibitors of apoptosis
TRAF2/3/5/6 TNF receptor associated factors 2/3/5/6
cFLIP Cellular FLICE-inhibitory protein
TCR T cell receptor
BCR B cell receptor
TAK1 Transforming growth factor beta-activated kinase 1
BAX BCL-2-associated X protein
BAK BCL-2 homologous antagonist/killer
APAF-1 apoptotic protease activating factor 1
ROS reactive oxygen species
BAD BCL-2-associated death promoter
BID BH3 interacting-domain death agonist
SMAC a second mitochondrial activator of caspases
AIF apoptosis inducing factor
MOMP mitochondrial outer membrane permeabilization
ncRNA non-coding RNA
miR microRNA
lncRNA long coding RNA
HURP Hepatoma upregulated protein
MPTP mitochondrial permeability transition pore
PI3K Phosphatidylinositol-4,5-bisphosphate 3-kinase
Akt Protein kinase B
TGF-β Transforming growth factor beta
SAPK stress-activated protein kinase
BAFFR TNF family receptor
LTβR lymphotoxin β-receptor
RANK receptor activator for nuclear factor κB
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NIK NF-kappa-B-inducing kinase
IKK IκB kinase
PTEN Phosphatase and tensin homolog
gp96 Heat shock protein 90kDa beta member 1
Mcl-1 Induced myeloid leukemia cell differentiation protein
p21 s cyclin-dependent kinase inhibitor 1
p27 Cyclin-dependent kinase inhibitor 1B
DR5 Death receptor 5/TRAIL receptor 2
IL-1/-6/-8 Interleukin-1/-6/-8
ER endoplasmic reticulum
Mdm2 Mouse double minute 2 homolog
LC3 II Microtubule-associated proteins 1A/1B light chain 3B
STAT3 Signal transducer and activator of transcription 3
CDC42 Cell division control protein 42 homolog
EGFP Enhanced green fluorescent protein
CAT-1 Cationic amino acid transporter 1
Smad7 Mothers against decapentaplegic homolog 7
MLK3 Mitogen-activated protein kinase kinase kinase 3
MKK7 Dual specificity mitogen-activated protein kinase kinase 7
ERK extracellular signal-regulated kinases
JNK c-Jun N-terminal kinases
MEKK MAP kinase kinase kinase
RACK Receptor for activated C-kinase
Drp-1 Dynamin-1-like protein
Elk ETS domain-containing protein
MAPKKs MAP kinase cascades
NTCP sodium taurocholate cotransporting polypeptide
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